<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82866">
  <stage>Registered</stage>
  <submitdate>30/05/2008</submitdate>
  <approvaldate>12/06/2008</approvaldate>
  <actrnumber>ACTRN12608000293369</actrnumber>
  <trial_identification>
    <studytitle>Intravenous Levetiracetam in the Acute Management of Seizures</studytitle>
    <scientifictitle>Intravenous Levetiracetam in the Acute Management of Seizures in Epilepsy</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>acute seizures</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous Levetiracetam will be administered in case of acute seizure (1000 mg over 5 minutes), for 1 dose only. Subjects will be observed and followed-up for the next 24 hrs following intravenous levetiracetam injection. Electroencephalographic recordings will be reviewed and subjects will be asked about adverse effects at 1, 12 and 24 hrs after intravenous administration of the agent.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Termination/Control of acute seizure after intravenous infusion of Levetiracetam 1000 mg over 5 minutes</outcome>
      <timepoint>Rapid termination of seizure after giving the medication</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Decrease frequency of seizure occurrence and interictal spikes per hour</outcome>
      <timepoint>24 hours following intravenous levetiracetam injection</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Epilepsy patients admitted for pre-surgical work-up at Monash Medical Centre with occurrence of acute seizures during epilepsy monitoring</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Women who are pregnanat or are considering pregnancy, lactation, moderate to severe renal dysfunction</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>20</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Prof. David C. Reutens</primarysponsorname>
    <primarysponsoraddress>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>UCB Pharma</fundingname>
      <fundingaddress>Level 1 1155 Malvern Road Malvern Victoria 3144</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr. Pilita Valencia</sponsorname>
      <sponsoraddress>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Yong Chern Lee</othercollaboratorname>
      <othercollaboratoraddress>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Simon Bower</othercollaboratorname>
      <othercollaboratoraddress>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr. Udaya Seneviratne</othercollaboratorname>
      <othercollaboratoraddress>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To examine the effectiveness and tolerability of Intravenous Levetiracetam in the acute seizure setting</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 4 Main Block
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</ethicaddress>
      <ethicapprovaldate>18/01/2008</ethicapprovaldate>
      <hrec>07203C</hrec>
      <ethicsubmitdate>20/12/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Prof. David C. Reutens</name>
      <address>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</address>
      <phone>+61395942240</phone>
      <fax>+61395946241</fax>
      <email>david.reutens@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. David C. Reutens</name>
      <address>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</address>
      <phone>+61395942240</phone>
      <fax>+61395946241</fax>
      <email>david.reutens@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof. David C. Reutens</name>
      <address>Department of Neurosciences
Level 5 Block E
Monash Medical Centre
246 Clayton Road
Clayton Victoria 3168</address>
      <phone>+61395942240</phone>
      <fax>+61395946241</fax>
      <email>david.reutens@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>